SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Study ID: 4769
NCT Number: NCT06506422
Principal Investigator: Camila Manrique, MD
Department: Medicine-Endocrinology

For questions about this study, please contact:

ClinicalTrialsInterest@health.missouri.edu
(573) 882-7026